Hantavirus vaccine

This is an old revision of this page, as edited by Ruslik0 (talk | contribs) at 19:15, 2 January 2014 (expanding). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Hantavirus vaccine is a vaccine that protects in humans against hantavirus infections causing Hantavirus hemorrhagic fever with renal syndrome (HFRS).

The first hantavirus vaccine was developed in 1990 initially for use against hantaan River virus which causes one of the most severe forms of HFRS.[1] It is estimated that about two million doses of rodent brain or cell-culture derived vaccine are given in China every year. The wide use of this vaccine may be partly responsible for a significant decrease in the number of HFRS cases in China to less than 20,000 by 2007.[2]

Other hantaviruses for which the vaccine is used include Seoul (SEOV) virus. However the vaccine is thought not to be effective against European hantaviruses including Puumala (PUUV) and Dobrava-Belgrade (DOBV) viruses. As of 2013 no hantavirus vaccine have been approved for use in Europe or USA.[2] The pharmaceutical trade name for the vaccine is Hantavax.[1][3]

In addition to Hantavax three vaccine have been studied in I–II stage clinical trials. They include a recombinant vaccine and vaccine derived from HTNV and PUUV viruses. However, their prospect are unclear.[2]


See also

References

  1. ^ a b Lee HW, Ahn CN, Song JW, Back LJ, Seo TJ, Park SC. Field trial of an inactivated vaccine against hemorrhagic fever with renal syndrome in humans. Arch Virol. 1990;1(Suppl):35–47.
  2. ^ a b c Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1586/ERV.12.15, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1586/ERV.12.15 instead.
  3. ^ Cho HW, Howard CR. Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax). Vaccine. 1999;17:2569–75.